We use analytics cookies to understand how readers use the site. They only run if you accept. Privacy policy.
The survival rate collapses once prostate cancer metastasizes — from near-certain survival to a 34% five-year rate.
The gap between localized and metastatic survival is the core medical problem — and why preventing metastasis is the highest-value therapeutic target.